Global Radiation Therapy Quality Assurance Phantoms Market Size By Type (Cubic Phantom, Disk Phantom), By Application (Prostate Cancer, Breast Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Radiation Therapy Quality Assurance (QA) Phantoms Market was valued at USD 132.5 million in 2023 and is projected to reach USD 231.7 million by 2031, growing at a CAGR of 7.2% during the forecast period from 2023 to 2031. The market's expansion is fueled by the increasing demand for precision in cancer treatment, advancements in radiotherapy technologies, and the growing global incidence of cancer. QA phantoms are crucial in validating and verifying the accuracy, consistency, and safety of radiation therapy systems, ensuring optimal treatment outcomes. Rising awareness of patient safety, coupled with stringent regulatory standards in oncology, is further boosting market growth.

Drivers

1. Rising Cancer Prevalence:

The global increase in cancer cases is a primary growth driver. Accurate radiation treatment is essential, and QA phantoms play a vital role in verifying treatment precision.

2. Technological Advancements in Radiation Therapy:

Modern radiotherapy techniques such as IMRT, VMAT, and proton therapy require sophisticated QA procedures. The evolution of high-precision machines enhances the need for advanced QA phantoms.

3. Regulatory Compliance and Safety Protocols:

Healthcare regulations mandate rigorous quality assurance protocols, creating sustained demand for QA phantoms across radiotherapy centers and hospitals.

Restraints

1. High Equipment Cost:

The high cost associated with manufacturing and acquiring QA phantoms can be a barrier for smaller healthcare facilities, especially in low-income regions.

2. Limited Expertise and Training:

The effective use of QA phantoms requires specialized knowledge. Lack of trained personnel in radiological physics may hinder adoption in developing markets.

Opportunity

1. Market Penetration in Emerging Economies:

The growing healthcare infrastructure in Asia-Pacific, Latin America, and parts of Africa offers lucrative opportunities for market players to expand through partnerships and local manufacturing.

2. Integration with AI and Automation Tools:

Advancements in QA software solutions that integrate with phantoms to automate analysis and reporting provide a competitive edge and open new avenues for product development.

Market by System Type Insights

The 3D Dosimetry Phantoms segment led the market in 2023, driven by its ability to provide accurate spatial dose distributions for complex radiotherapy procedures. These phantoms are essential for validating highly conformal techniques and adaptive radiotherapy. Meanwhile, the End-to-End QA Phantoms segment is expected to witness the fastest growth due to increasing demand for comprehensive system-wide QA solutions.

Market by End-use Insights

Hospitals and Radiotherapy Centers accounted for the largest revenue share in 2023. These facilities are the primary users of QA phantoms, especially those offering advanced radiotherapy treatments. Academic and Research Institutions are also contributing to market demand through clinical trials and innovation in radiation therapy methods.

Market by Regional Insights

North America dominated the global radiation therapy QA phantoms market in 2023, owing to a strong oncology infrastructure, high adoption of cutting-edge radiation technologies, and rigorous quality mandates. However, Asia-Pacific is projected to register the highest CAGR over the forecast period, driven by increasing cancer prevalence, healthcare investment, and technological adoption in countries like China and India.

Competitive Scenario

Prominent players in the market include PTW Freiburg GmbH, IBA Dosimetry, Standard Imaging Inc., Sun Nuclear Corporation, CIRS Inc., and Modus Medical Devices Inc. These companies focus on product innovation, automation integration, and global expansion.

Key Developments:

In 2023, PTW launched a new 4D motion QA phantom designed to simulate respiratory movement for real-time dose verification.

In 2024, IBA Dosimetry collaborated with major oncology centers to develop AI-assisted phantom analysis software.

In 2025, CIRS introduced modular phantom kits for proton and heavy ion therapy applications, addressing niche high-growth segments.

Scope of Work – Global Radiation Therapy Quality Assurance Phantoms Market

Report Metric Details

Market Size (2023) USD 132.5 million

Projected Market Size (2031) USD 231.7 million